别嘌呤醇与持续躯体失能及衰弱的关系:一项大型社区老年队列分析
本研究基于ASPREE随机试验数据,纳入1155例基线痛风老年参与者,分析别嘌呤醇使用与持续躯体失能及新发衰弱的关联。中位随访5.7年,基线别嘌呤醇使用与持续躯体失能风险显著降低相关(Adjusted HR 0.46,95%CI 0.23-0.92,p=0.03),但与衰弱指标无显著关联。
要点
- 基线别嘌呤醇使用与持续躯体失能风险降低相关(Adjusted HR 0.46,95%CI 0.23-0.92,p=0.03)。
- 时变分析中该关联强度减弱(Adjusted HR 0.56,95%CI 0.29-1.08,p=0.08)。
- 别嘌呤醇使用与Fried衰弱表型及衰弱指数均无显著关联。
核心结论
- 老年痛风患者使用别嘌呤醇与持续躯体失能风险降低相关,但与衰弱风险无关。
研究设计与样本
- 基于ASPREE随机试验数据的分析,纳入19114名≥65岁无既往心血管事件、痴呆或限制独立生活的躯体失能者,本分析聚焦基线痛风参与者1155例(基线使用别嘌呤醇630例,未使用525例),中位随访5.7年。
主要发现
- 基线别嘌呤醇使用与持续躯体失能风险显著降低相关(Adjusted HR 0.46,95%CI 0.23-0.92,p=0.03)。
- 时变分析中该关联强度 modestly 减弱(Adjusted HR 0.56,95%CI 0.29-1.08,p=0.08)。
- 基线别嘌呤醇使用与Fried衰弱表型(Adjusted HR 0.83,95%CI 0.62-1.12)及衰弱指数(Adjusted HR 0.96,95%CI 0.74-1.24)均无显著关联。
- 时变别嘌呤醇使用与Fried衰弱表型(Adjusted HR 0.92,95%CI 0.69-1.24)及衰弱指数(Adjusted HR 1.02,95%CI 0.78-1.33)均无显著关联。
关键数值与推荐
- 持续躯体失能:基线别嘌呤醇使用 Adjusted HR 0.46(95%CI 0.23-0.92,p=0.03);时变分析 Adjusted HR 0.56(95%CI 0.29-1.08,p=0.08)。
- 衰弱评估采用Fried衰弱表型(评分≥3/5)和缺陷累积衰弱指数(FI评分>0.21/1.0)。
- Fried衰弱:基线使用 Adjusted HR 0.83(95%CI 0.62-1.12);时变使用 Adjusted HR 0.92(95%CI 0.69-1.24)。
- 衰弱指数:基线使用 Adjusted HR 0.96(95%CI 0.74-1.24);时变使用 Adjusted HR 1.02(95%CI 0.78-1.33)。
临床怎么用
- 在老年痛风患者中,别嘌呤醇使用可能与持续躯体失能风险降低相关,但证据来自观察性分析,需结合个体情况评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The protective effects of allopurinol on physical function in older adults are not well understood, despite its potential to improve functional gains and reduce sarcopenia. This study aims to determine the association between allopurinol, persistent physical disability, and frailty in older gout patients. METHODS: This analysis used data from a randomized trial in an older cohort, ASPirin in Reducing Events in the Elderly (ASPREE). ASPREE recruited 19,114 participants aged ≥65 years without prior cardiovascular events, dementia, or independence-limiting physical disability at trial enrolment. This analysis examined the association of baseline and time-varying allopurinol use with persistent physical disability and new-onset frailty in participants with gout at baseline (self-report or use of any anti-gout medications). Frailty was measured using the Fried frailty phenotype (score ≥3/5) and a deficit accumulation frailty index (FI) (score >0.21/1.0). Multivariable Cox proportional-hazards models were used for main analyses. RESULTS: This analysis included 1155 gout participants, with 630 taking allopurinol at baseline and 525 not. During a median follow-up of 5.7 years, 113 new allopurinol users were identified. Compared with nonusers, baseline allopurinol use was associated with a significant risk reduction of persistent physical disability (Adjusted HR 0.46, 95% CI 0.23-0.92, p = 0.03). The strength of the association was modestly attenuated in the time-varying analysis (Adjusted HR 0.56, 0.29-1.08, p = 0.08). No significant associations with frailty measures were observed for either baseline allopurinol use (Fried frailty: Adjusted HR 0.83, 0.62-1.12; FI: Adjusted HR 0.96, 0.74-1.24) or time-varying allopurinol use (Fried frailty: Adjusted HR 0.92, 0.69-1.24; FI: Adjusted HR 1.02, 0.78-1.33). CONCLUSIONS: Allopurinol use in older adults with gout is associated with a reduced risk of persistent physical disability but not associated with risk of frailty.
引用
- Zhou Z, Ryan J, Nelson MR, et al. The association of allopurinol with persistent physical disability and frailty in a large community based older cohort. J Am Geriatr Soc. 2023. PMID: 37158186. doi:10.1111/jgs.18395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。